ASP Isotopes Inc. Enters Into Purchase Agreement With a Leading Semiconductor Company for the Supply of Highly Enriched Electronic Gases
01 Abril 2024 - 9:00AM
ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”),
an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in
multiple industries, today announced that it has entered into a
purchase agreement with an industry leader in the design and
manufacturing of semiconductors. Under the terms of the agreement,
ASP Isotopes expects to supply highly enriched silicon-28 to the
customer for use in next-generation semiconductors. The product is
expected to be supplied from the Company’s South African production
facility and shipped to the customer in the USA during 2024.
Naturally occurring silicon has three isotopes –
28, 29 and 30. The 29 isotope has a ½ positive spin, which is an
intrinsic form of angular momentum carried by elementary particles.
Highly enriched silicon-28 is spin-free where qubits are protected
from sources of decoherence that causes loss of quantum
information(1). In addition to its potential to process superior
information such as qubits, it is believed that highly enriched
silicon-28 can conduct heat 150% more efficiently(2) than natural
silicon, which will potentially allow for chips to become smaller,
faster and cooler.
ASP Isotopes’s proprietary technology can enrich
isotopes of low atomic mass (such as silane (SiH4), molecular mass
of 32), as well as isotopes of heavier masses. Other companies
developing methods to enrich silicon generally either enrich
silicon tetrafluoride (SiF4) or a halo silane. Neither of these
chemicals can be used directly by a semiconductor company and
require chemical converting processes that potentially harm the
purity of the final product. By processing silane directly, the
Company believes that its finished product will be a higher quality
and may be used by semiconductor companies without the need for
additional chemical conversion processes.
“To create faster, smaller next-generation
semiconductors, the world is likely going to require materials that
are currently not available in commercial quantities,” said Paul
Mann, ASP Isotopes’ Chairman and Chief Executive Officer. “ASP
Isotopes is currently working on many isotopically pure elements
that we believe will help semiconductor companies create the chips
that the world will require in the future to enable technologies
such as Quantum Computing and Artificial Intelligence.”
ASPI’s South African multi-isotope production
facility is expected to be capable of producing up to 10 Kgs of
highly enriched silicon-28 per annum. To meet the anticipated
demand later this decade, the Company anticipates constructing a
larger production facility as part of the proposed Icelandic
cluster, slated to start production during 2026. The Company
expects to start the construction of its Icelandic facilities
during 2024 with first production of medical isotopes expected in
2025. The Company is in discussions with many companies, both in
the semiconductor industry as well as healthcare industries
regarding their requirements for products that might be produced
from the Icelandic cluster.
(1) |
Isotopically Enriched Layers for Quantum Computers Formed by 28Si
Implantation and Layer Exchange, Schneider, E and England, J; ACS
Appl. Mater. Interfaces 2023, 15, 17, 21609–21617 |
(2) |
Penghong Ci, Muhua Sun, Meenakshi
Upadhyaya, Houfu Song, Lei Jin, Bo Sun, Matthew R. Jones, Joel W.
Ager, Zlatan Aksamija, and Junqiao Wu Phys. Rev. Lett. 128, 085901
– Published 23 February 2022 |
|
|
About ASP Isotopes Inc.
ASP Isotopes Inc. is a pre-commercial stage
advanced materials company dedicated to the development of
technology and processes to produce isotopes for use in multiple
industries. The Company employs proprietary technology, the
Aerodynamic Separation Process (“ASP technology”). The Company’s
initial focus is on producing and commercializing highly enriched
isotopes for the healthcare and technology industries. The Company
also plans to enrich isotopes for the nuclear energy sector using
Quantum Enrichment technology that the Company is developing. The
Company has isotope enrichment facilities in Pretoria, South
Africa, dedicated to the enrichment of isotopes of elements with a
low atomic mass (light isotopes).
There is a growing demand for isotopes such as
Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and
Nickel-64 for new, emerging healthcare applications, as well as
Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. The ASP Technology (Aerodynamic Separation Process)
is ideal for enriching low and heavy atomic mass molecules. For
more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including,
without limitation, statements relating to the development of new
technology for the enrichment of nuclear isotopes, the commencement
of supply of isotopes to customers, and the construction of
additional enrichment facilities. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations,
and assumptions regarding the future of our business, future plans
and strategies, projections, anticipated events and trends, the
economy, and other future conditions. Forward-looking statements
can be identified by words such as “believes,” “plans,”
“anticipates,” “expects,” “estimates,” “projects,” “will,” “may,”
“might,” and words of a similar nature. Examples of forward-looking
statements include, among others but are not limited to, statements
we make regarding expected operating results, such as future
revenues and prospects from the potential commercialization of
isotopes, future performance under contracts, and our strategies
for product development, engaging with potential customers, market
position, and financial results. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks, and changes in circumstances that are difficult to predict,
many of which are outside our control. Our actual results,
financial condition, and events may differ materially from those
indicated in the forward-looking statements based upon a number of
factors. Forward-looking statements are not a guarantee of future
performance or developments. You are strongly cautioned that
reliance on any forward-looking statements involves known and
unknown risks and uncertainties. Therefore, you should not rely on
any of these forward-looking statements. There are many important
factors that could cause our actual results and financial condition
to differ materially from those indicated in the forward-looking
statements, including our reliance on the efforts of third parties;
our ability to complete the construction and commissioning of our
enrichment plants or to commercialize isotopes using the ASP
technology or the Quantum Enrichment Process; our ability to obtain
regulatory approvals for the production and distribution of
isotopes; the financial terms of any current and future commercial
arrangements; our ability to complete certain transactions and
realize anticipated benefits from acquisitions; contracts,
dependence on our Intellectual Property (IP) rights, certain IP
rights of third parties; and the competitive nature of our
industry. Any forward-looking statement made by us in this press
release is based only on information currently available to us and
speaks only as of the date on which it is made. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise. This press release includes market and industry data and
forecasts that we obtained from internal research, publicly
available information and industry publications and surveys.
Industry publications and surveys generally state that the
information contained therein has been obtained from sources
believed to be reliable. Unless otherwise noted, statements as to
our potential market position relative to other companies are
approximated and based on third-party data and internal analysis
and estimates as of the date of this press release. We have not
independently verified this information, and it could prove
inaccurate. Industry and market data could be wrong because of the
method by which sources obtained their data and because information
cannot always be verified with certainty due to the limits on the
availability and reliability of raw data, the voluntary nature of
the data-gathering process and other limitations and uncertainties.
In addition, we do not know all of the assumptions regarding
general economic conditions or growth that were used in preparing
the information and forecasts from sources cited herein. No
information in this press release should be interpreted as an
indication of future success, revenues, results of operation, or
stock price. All forward-looking statements herein are qualified by
reference to the cautionary statements set forth herein and should
not be relied upon.
Contacts
Jason Assad– Investor
relationsEmail: Jassad@aspisotopes.comTelephone:
561-709-3043
ASP Isotopes (NASDAQ:ASPI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ASP Isotopes (NASDAQ:ASPI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024